US5149538A
(en)
*
|
1991-06-14 |
1992-09-22 |
Warner-Lambert Company |
Misuse-resistive transdermal opioid dosage form
|
DE4423850A1
(de)
*
|
1994-07-07 |
1996-01-11 |
Labtec Gmbh |
Transdermales therapeutisches System zur Applikation von Naloxon
|
US5656416A
(en)
*
|
1994-12-22 |
1997-08-12 |
Eastman Kodak Company |
Photographic processing composition and method using organic catalyst for peroxide bleaching agent
|
US6284266B1
(en)
*
|
1995-07-28 |
2001-09-04 |
Zars, Inc. |
Methods and apparatus for improved administration of fentanyl and sufentanil
|
DE69709646T2
(de)
*
|
1996-03-12 |
2002-08-14 |
Alza Corp |
Zusammensetzung und dosisform mit einem opioid-antagonisten
|
US5968547A
(en)
|
1997-02-24 |
1999-10-19 |
Euro-Celtique, S.A. |
Method of providing sustained analgesia with buprenorphine
|
GB9707934D0
(en)
*
|
1997-04-18 |
1997-06-04 |
Danbiosyst Uk |
Improved delivery of drugs to mucosal surfaces
|
DE19743484C1
(de)
*
|
1997-10-01 |
1999-01-28 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
|
US7011843B2
(en)
*
|
1997-10-01 |
2006-03-14 |
Lts Lohmann-Therapie Systeme Ag |
Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
|
CN1204890C
(zh)
|
1997-12-22 |
2005-06-08 |
欧罗赛铁克股份有限公司 |
防止阿片样物质滥用的方法
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
AU773642C
(en)
|
1997-12-22 |
2006-04-06 |
Mundipharma Pty Limited |
Opioid agonist/antagonist combinations
|
DE19960154A1
(de)
*
|
1999-12-14 |
2001-07-12 |
Lohmann Therapie Syst Lts |
Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
PT2092936E
(pt)
|
2000-02-08 |
2013-06-20 |
Euro Celtique Sa |
Formulações orais de agonistas de opióides resistentes a adulteração
|
US20020119187A1
(en)
*
|
2000-09-29 |
2002-08-29 |
Cantor Adam S. |
Composition for the transdermal delivery of fentanyl
|
GB0026137D0
(en)
*
|
2000-10-25 |
2000-12-13 |
Euro Celtique Sa |
Transdermal dosage form
|
EP1424973B1
(de)
*
|
2001-04-23 |
2010-03-03 |
Euro-Celtique S.A. |
Entsorgungssystem für transdermale dosierformen
|
EP2316439B1
(de)
*
|
2001-05-01 |
2015-06-17 |
Euro-Celtique S.A. |
Missbrauchssichere, opioidenthaltende transdermale Systeme
|
CA2446550C
(en)
|
2001-05-11 |
2012-03-06 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant controlled-release opioid dosage form
|
EP1418862A4
(de)
*
|
2001-06-29 |
2010-06-09 |
Leon J Lewandowski |
Individualisierte suchttherapie
|
PL207748B1
(pl)
*
|
2001-07-06 |
2011-01-31 |
Penwest Pharmaceuticals Company |
Preparat o przedłużonym uwalnianiu zawierający oksymorfon oraz jego zastosowanie
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
WO2003004032A1
(en)
*
|
2001-07-06 |
2003-01-16 |
Endo Pharmaceuticals, Inc. |
Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
|
DE60230632D1
(de)
|
2001-07-18 |
2009-02-12 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
US20030068276A1
(en)
|
2001-09-17 |
2003-04-10 |
Lyn Hughes |
Dosage forms
|
JP2005523876A
(ja)
*
|
2001-09-26 |
2005-08-11 |
ペンウェスト ファーマシューティカルズ カンパニー |
乱用の可能性が低減したオピオイド製剤
|
WO2003032926A2
(en)
*
|
2001-10-19 |
2003-04-24 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for reversal of drug resistance
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
CN102813654A
(zh)
|
2002-04-05 |
2012-12-12 |
欧洲凯尔蒂克公司 |
含有羟氢可待酮和烯丙羟吗啡酮的药物制剂
|
AR039336A1
(es)
*
|
2002-04-23 |
2005-02-16 |
Alza Corp |
Sistemas analgesicos transdermicos con potencial de abuso reducido
|
NZ536965A
(en)
*
|
2002-05-31 |
2007-02-23 |
Titan Pharmaceuticals Inc |
Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
|
MXPA04012333A
(es)
*
|
2002-06-10 |
2005-02-25 |
Euro Celtique Sa |
Sistemas de colocacion de dispositivos de liberacion transdermica para prevenir el uso incorrecto de los agentes activos contenidos en los mismos.
|
US20040126323A1
(en)
*
|
2002-08-20 |
2004-07-01 |
Ihor Shevchuk |
Transdermal dosage form comprising an active agent and a salt and free-base form of an adverse agent
|
US20050020613A1
(en)
*
|
2002-09-20 |
2005-01-27 |
Alpharma, Inc. |
Sustained release opioid formulations and method of use
|
ES2677769T3
(es)
|
2002-09-20 |
2018-08-06 |
Alpharma Pharmaceuticals Llc |
Subunidad secuestrante y composiciones y procedimientos relacionados
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
DE602004024963D1
(de)
*
|
2003-03-13 |
2010-02-25 |
Controlled Chemicals Inc |
Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
|
CN102772357B
(zh)
|
2003-03-31 |
2014-12-31 |
泰坦医药品公司 |
用于持续释放多巴胺受体激动剂的可植入聚合物装置
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
US8790689B2
(en)
*
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
US8778382B2
(en)
|
2003-04-30 |
2014-07-15 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
US7182955B2
(en)
*
|
2003-04-30 |
2007-02-27 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
US20040219195A1
(en)
*
|
2003-04-30 |
2004-11-04 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
US8906413B2
(en)
*
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
US20070191815A1
(en)
|
2004-09-13 |
2007-08-16 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery
|
JP2007527415A
(ja)
|
2003-10-30 |
2007-09-27 |
アルザ・コーポレーシヨン |
乱用の可能性が低い経皮鎮痛剤システム
|
US8535711B2
(en)
*
|
2004-01-23 |
2013-09-17 |
Teikoku Pharma Usa, Inc. |
Medication disposal system
|
US7867511B2
(en)
*
|
2004-01-23 |
2011-01-11 |
Travanti Pharma Inc. |
Abuse potential reduction in abusable substance dosage form
|
RS50963B
(sr)
*
|
2004-02-23 |
2010-10-31 |
Euro-Celtique S.A. |
Opioidni transdermalni preparat otporan na zloupotrebu
|
EP1604667A1
(de)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung des Restless Leg Syndroms
|
EP1604666A1
(de)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US20070269522A1
(en)
*
|
2004-08-20 |
2007-11-22 |
Wold Chad R |
Transdermal Drug Delivery Device with Translucent Protective Film
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US7226619B1
(en)
|
2004-09-07 |
2007-06-05 |
Pharmorx Inc. |
Material for controlling diversion of medications
|
US8252321B2
(en)
|
2004-09-13 |
2012-08-28 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
|
US8541026B2
(en)
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
EP1809259B1
(de)
*
|
2004-10-15 |
2014-12-03 |
Supernus Pharmaceuticals, Inc. |
Pharmazeutische zubereitungen mit geringerem missbrauchspotential
|
NZ582975A
(en)
|
2004-10-21 |
2011-07-29 |
Durect Corp |
Transdermal delivery systems delivering sufentanil
|
US8252320B2
(en)
|
2004-10-21 |
2012-08-28 |
Durect Corporation |
Transdermal delivery system for sufentanil
|
US7827983B2
(en)
*
|
2004-12-20 |
2010-11-09 |
Hewlett-Packard Development Company, L.P. |
Method for making a pharmaceutically active ingredient abuse-prevention device
|
EP2319499A1
(de)
*
|
2005-01-28 |
2011-05-11 |
Euro-Celtique S.A. |
Alkoholresistente Arzneiformen
|
TW200640526A
(en)
*
|
2005-02-24 |
2006-12-01 |
Alza Corp |
Transdermal electrotransport drug delivery systems with reduced abuse potential
|
EP1702558A1
(de)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
EP1695700A1
(de)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Darreichungsform enthaltend Oxycodon und Naloxon
|
US20060223786A1
(en)
*
|
2005-04-01 |
2006-10-05 |
Smith David J |
Transdermal pain control method and device
|
WO2006124584A2
(en)
*
|
2005-05-13 |
2006-11-23 |
Alza Corporation |
Multilayer drug delivery system with barrier against reservoir material flow
|
US9522188B2
(en)
*
|
2005-12-13 |
2016-12-20 |
Biodelivery Sciences International, Inc. |
Abuse resistant transmucosal drug delivery device
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US8535714B2
(en)
|
2006-01-06 |
2013-09-17 |
Acelrx Pharmaceuticals, Inc. |
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
|
US8753308B2
(en)
|
2006-01-06 |
2014-06-17 |
Acelrx Pharmaceuticals, Inc. |
Methods for administering small volume oral transmucosal dosage forms using a dispensing device
|
US8202535B2
(en)
|
2006-01-06 |
2012-06-19 |
Acelrx Pharmaceuticals, Inc. |
Small-volume oral transmucosal dosage forms
|
US8865743B2
(en)
|
2006-01-06 |
2014-10-21 |
Acelrx Pharmaceuticals, Inc. |
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
|
US9066847B2
(en)
*
|
2007-01-05 |
2015-06-30 |
Aceirx Pharmaceuticals, Inc. |
Storage and dispensing devices for administration of oral transmucosal dosage forms
|
US8252329B2
(en)
|
2007-01-05 |
2012-08-28 |
Acelrx Pharmaceuticals, Inc. |
Bioadhesive drug formulations for oral transmucosal delivery
|
US8252328B2
(en)
*
|
2006-01-06 |
2012-08-28 |
Acelrx Pharmaceuticals, Inc. |
Bioadhesive drug formulations for oral transmucosal delivery
|
US9289583B2
(en)
|
2006-01-06 |
2016-03-22 |
Acelrx Pharmaceuticals, Inc. |
Methods for administering small volume oral transmucosal dosage forms using a dispensing device
|
US8357114B2
(en)
*
|
2006-01-06 |
2013-01-22 |
Acelrx Pharmaceuticals, Inc. |
Drug dispensing device with flexible push rod
|
US7740879B2
(en)
*
|
2006-01-17 |
2010-06-22 |
Harrogate Holdings |
Abuse resistant transdermal drug delivery patch
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
CN104825397A
(zh)
|
2006-04-03 |
2015-08-12 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
US20070248657A1
(en)
*
|
2006-04-25 |
2007-10-25 |
Smith David J |
Multi-compartment transdermal pain control device
|
US20070260491A1
(en)
*
|
2006-05-08 |
2007-11-08 |
Pamela Palmer |
System for delivery and monitoring of administration of controlled substances
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
DE102006025282A1
(de)
|
2006-05-31 |
2007-12-20 |
Lts Lohmann Therapie-Systeme Ag |
Selbstzerstörendes transdermales therapeutisches System
|
US20070278289A1
(en)
*
|
2006-05-31 |
2007-12-06 |
Toshiba Tec Kabushiki Kaisha |
Payment adjusting apparatus and program therefor
|
SI2484346T1
(sl)
|
2006-06-19 |
2017-05-31 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
US20070299687A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Pamela Palmer |
Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
|
RS54764B1
(sr)
|
2006-07-21 |
2016-10-31 |
Biodelivery Sciences Int Inc |
Sredstvo za transmukozalnu isporuku sa povećanim nakupljanjem
|
EP1897543A1
(de)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine-Waffel zur Substitutionstherapie
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
EP3269346A1
(de)
*
|
2007-08-07 |
2018-01-17 |
Acelrx Pharmaceuticals, Inc. |
Vorrichtung zur oralen medikamentengabe
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US9226907B2
(en)
|
2008-02-01 |
2016-01-05 |
Abbvie Inc. |
Extended release hydrocodone acetaminophen and related methods and uses thereof
|
WO2009106831A2
(en)
|
2008-02-28 |
2009-09-03 |
Syntropharma Limited |
Pharmaceutical composition
|
US20090246265A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Alltranz Inc. |
Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
|
DE102008016804B4
(de)
|
2008-04-02 |
2012-01-05 |
Lts Lohmann Therapie-Systeme Ag |
Selbstzerstörendes transdermales therapeutisches System mit verbesserter Funktionalität und Wirksamkeit sowie seine Verwendung
|
CN105833420A
(zh)
*
|
2008-06-23 |
2016-08-10 |
生物递送科学国际公司 |
多向粘膜给药装置及使用方法
|
US8945592B2
(en)
*
|
2008-11-21 |
2015-02-03 |
Acelrx Pharmaceuticals, Inc. |
Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
|
US20100221313A1
(en)
*
|
2008-12-01 |
2010-09-02 |
Innovative Pharmaceuticals, Llc |
Transdermal reservoir patch
|
SI2405915T1
(sl)
|
2009-03-10 |
2019-03-29 |
Euro-Celtique S.A. |
Farmacevtski sestavki s takojšnjim sproščanjem, ki vsebujejo oksikodon in nalokson
|
DE102009036485B4
(de)
|
2009-08-07 |
2012-10-04 |
Lts Lohmann Therapie-Systeme Ag |
Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
|
US20110091544A1
(en)
*
|
2009-10-16 |
2011-04-21 |
Acelrx Pharmaceuticals, Inc. |
Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
|
US9277748B2
(en)
|
2010-03-12 |
2016-03-08 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Agonist/antagonist compositions and methods of use
|
EP2557924B1
(de)
|
2010-04-13 |
2019-06-12 |
Relmada Therapeutics, Inc. |
Dermale pharmazeutische zusammensetzungen aus 1-methyl-2',6'-pipecoloxylidid und verwendungsverfahren dafür
|
WO2012154986A1
(en)
*
|
2011-05-10 |
2012-11-15 |
Antecip Bioventures Ii Llc |
Implantable polymeric device for sustained release of sufentanil
|
EP2729148A4
(de)
|
2011-07-06 |
2015-04-22 |
Parkinson S Inst |
Zusammensetzungen und verfahren zur behandlung von symptomen bei patienten mit morbus parkinson
|
ES2660116T3
(es)
|
2011-08-18 |
2018-03-20 |
Biodelivery Sciences International, Inc. |
Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina
|
CA2846957C
(en)
|
2011-09-30 |
2017-04-11 |
Teikoku Pharma Usa, Inc. |
General medication disposal system
|
JP5964435B2
(ja)
|
2011-09-30 |
2016-08-03 |
テイコク ファーマ ユーエスエー インコーポレーテッド |
経皮パッチ廃棄システム
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
JP2016525138A
(ja)
|
2013-07-23 |
2016-08-22 |
ユーロ−セルティーク エス.エイ. |
疼痛および腸内ディスバイオシスをもたらす疾患および/または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
US10010543B1
(en)
|
2014-12-23 |
2018-07-03 |
Barr Laboratories, Inc. |
Transdermal dosage form
|
WO2016123406A1
(en)
|
2015-01-28 |
2016-08-04 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
CA2977814A1
(en)
|
2015-03-12 |
2016-09-15 |
Chrono Therapeutics Inc. |
Craving input and support system
|
JP2020503950A
(ja)
|
2017-01-06 |
2020-02-06 |
クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. |
経皮薬剤送達の装置及び方法
|
US11389844B2
(en)
|
2018-03-20 |
2022-07-19 |
Verde Environmental Technologies, Inc. |
Blister pack disposal system
|
WO2019232077A1
(en)
|
2018-05-29 |
2019-12-05 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
WO2020008370A1
(en)
|
2018-07-02 |
2020-01-09 |
Clexio Biosciences Ltd. |
Transdermal patch
|
WO2020009685A1
(en)
|
2018-07-02 |
2020-01-09 |
John Tang |
Transdermal dosage form
|
WO2020008366A1
(en)
|
2018-07-02 |
2020-01-09 |
Clexio Biosciences Ltd. |
Transdermal dosage form
|
CN113453665A
(zh)
|
2019-02-21 |
2021-09-28 |
药品生产公司 |
用于舌下和/或经颊施用的纳洛酮制剂
|